Abstract
Activated carbon particles adsorbing anticancer drugs release the anticancer components at designated levels for a long period at the target tissues, while distribute at a low level to the whole body. Moreover, the particles target the car-cinomatous tumor because of the tendency to adhere the tumor surface. In animal experiments, relatively large particles of activated carbon adsor-bing mitomycin C(MMC-CH)decreased the toxiaty into 18.5%, and its therapeutic efficacy on carcinomatous effusion(LD50/ED50)was 3 times, as compared with those in mitomycin C aqueous solution. Intraperitoneal MMC-CH extended the survival time of rabbits with peritoneal carcinomatosis longer than mitomycin C aqueous solution did. In clinical trials, 51 of 81 patients with carcinomatous effusion(63%)responded well to the MMC-CH therapy. The survival time of the patients with gastric cancer invading into the peritoneum was increased by intraoperative MMC-CH therapy statistically significantry higer than that of historical control group. Very small activated carbon particles adsorbing peplomycin(PEP-CH) showed superior therapeutic effects on lymphatic metastases and a low pulmonary toxicity, as compared with peplomycin aqueous solution. Seven inoperative patients underwent local injection of PEP-CH against esophagael cancer. The response rate was 86% and the mean survival time was 14.3 months.
